Stoke Therapeutics’ (STOK) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note published on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock. STOK has been the subject of a number of other reports. Leerink Partnrs raised Stoke […]

Leave a Reply

Your email address will not be published.

Previous post Mark W. Jenkins Sells 20,000 Shares of Carvana Co. (NYSE:CVNA) Stock
Next post UBS Group Forecasts Strong Price Appreciation for Xometry (NASDAQ:XMTR) Stock